化学
相(物质)
对偶(语法数字)
药理学
医学
材料科学
计算机科学
生物医学工程
药代动力学
生物系统
作者
Stephanie A. Mowery,Patrick J. Knerr,Karina Rahr Hjøllund,Birgitte Nissen,Anette K. Olsen,Trine Levring Wilkens,Lasse Hjort Jakobsen,Christian Hollesen,Kateryna Breusova,Joyce E. Sorrell,Diego Pérez–Tilve,Brian Finan,Richard D. DiMarchi,Charlotta Dornonville de la Cour
标识
DOI:10.1016/j.molmet.2026.102470
摘要
OBJECTIVES: The efficacy and convenience of anti-diabetic and anti-obesity therapeutics have surged in recent years due to the emergence of incretin-based poly-pharmacological approaches as well as advances in the oral delivery of peptide drugs. We sought to combine both strategies in an orally deliverable dual agonist of the GLP-1 and GIP receptors. METHODOLOGY: We designed a panel of unimolecular, fatty-acylated peptide dual agonists, which was screened for receptor potencies in cell-based assay systems. NNC0130 was selected to advance into clinical studies using both oral and subcutaneous administration. RESULTS: NNC0130 exhibited in vitro potency comparable to semaglutide at human GLP-1R and to tirzepatide at human GIPR, with a chemical structure compatible with semi-recombinant production. Its human half-life of 76-89 h was deemed suitable for once-daily oral administration. In a multiple-ascending dose trial in participants with overweight or obesity and with separate subcutaneous and oral cohorts, daily subcutaneous administration of NNC0130 escalating from 0.3 to 3.0 mg per dose provided a placebo-corrected mean body weight loss of 9% after 12 weeks of treatment and 12% after 15 weeks. Daily oral administration escalating from 5 to 50 mg per dose provided a placebo-corrected mean body weight loss of 4% after 12 weeks, which was not statistically significantly different from zero. The relative oral bioavailability when co-formulated with permeation enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate was estimated to 1.6-2.2% versus s. c. administration. CONCLUSIONS: The modest weight-lowering efficacy of orally administered NNC0130 highlights the continued challenges of low oral bioavailability of acylated peptides. However, the substantial efficacy observed with subcutaneous administration motivated advancement into Phase 2 clinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI